Prostate Cell News 8.40 October 20, 2017 | |
| |
TOP STORYPTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K Researchers found that PTEN deletion increased PI(3,4)P2 levels in a mouse model of prostate cancer, and it inversely correlated with PI(3,4)P2 levels across several epidermal growth factor-stimulated prostate and breast cancer lines. [Mol Cell] Full Article | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Deletion of 3p13-14 Locus Spanning FOXP1 to SHQ1 Cooperates with PTEN Loss in Prostate Oncogenesis Scientists demonstrated that Foxp1-Shq1 deletion accelerates prostate tumorigenesis in mice in combination with Pten loss, consistent with the association of FOXP1–SHQ1 and PTEN loss observed in human cancers. [Nat Commun] Full Article The authors identified the myristoyl-CoA analog B13 as a small molecule inhibitor of N-myristoyltransferase (NMT)1 enzymatic activity. B13 exposure blocked Src myristoylation and Src localization to the cytoplasmic membrane, attenuating Src-mediated oncogenic signaling. B13 exerted its antiinvasive and antitumor effects against prostate cancer cells with minimal toxic side-effects in vivo. [Cancer Res] Abstract Scientists demonstrated that forkhead box (FOXO)1, but not other FOXO proteins (FOXO3 and FOXO4), binds and inhibits the transcriptional activity of prostate cancer-associated ERG independently of FOXO1 transcriptional activity. Knockdown of endogenous FOXO1 increased invasion of TMPRSS2-ERG fusion positive VCaP cells, an effect completely abolished by ERG knockdown. [Cancer Res] Abstract Nuclear Receptor Profiling in Prostatospheroids and Castration-Resistant Prostate Cancer Researchers surveyed the expression profiles of the entire nuclear receptor superfamily in three-dimensional cultured prostatospheroids derived from different prostate cancer cell lines and a tumor xenograft model of castration-resistant prostate cancer VCaP-CRPC by quantitative real-time RT-PCR. [Endocr Relat Cancer] Abstract Investigators generated and evaluated a PLAC1-based antibody drug conjugate for targeted immunotherapy of prostate cancer. Prostate cancer cells expressed considerable levels of PLAC1. The Anti-PLAC1 clone, 2H12C12, showed high reactivity with recombinant PLAC1 and selectivity recognized PLAC1 in prostate cancer cells but not in LS180 cells, the negative control. [Sci Rep] Full Article Researchers developed a new aptamer-based biosensor through the self-assembling of thiolated aptamers for PSA and VEGF on the top of gold electrodes. This biosensor was tested in three prostate cell lines. The aptasensor was able to detect the patterns of PSA and VEGF released in vitro by prostate cancer cells, which gave new insights about the prostate cancer protein dynamics. [Anal Bioanal Chem] Abstract | Graphical Abstract The authors assessed the role of epigallocatechin-3-gallate, suppressing the formation of benign prostatic hyperplasia by reducing inflammation and oxidative stress, in cytoskeleton organization and extracellular matrix interactions via focal adhesions. [Life Sci] Abstract F-Actin Reorganization by V-ATPase Inhibition in Prostate Cancer Scientists studied vacuolar ATPase (V-ATPase) in the prostate cancer (PCa) cell line PC-3, which has characteristics of highly metastatic PCa. V-ATPase inhibitors impaired endo-lysosomal pH, vesicle trafficking, migration, and invasion. [Biol Open] Full Article | |
| |
REVIEWSAlternative Mechanisms of MiR-34a Regulation in Cancer The authors review p53-independent mechanisms regulating the expression of miR-34a. Aside from molecules directly interacting with MIR34A promoter, processes affecting epigenetic regulation and miRNA maturation are discussed. [Cell Death Dis] Full Article Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSTrovagene, Inc. announced positive data from preclinical research demonstrating synergy of PCM-075, its oral, highly-selective polo-like kinase 1 (PLK1) Inhibitor, in combination with Zytiga®. [Trovagene, Inc. (PR Newswire Association LLC)] Press Release NanOlogy LLC announced the first patient has been enrolled in a clinical trial of NanoPac® sterile suspension administered into the prostate for treatment of prostate cancer. [NanOlogy LLC] Press Release | |
| |
POLICY NEWSRand Paul Takes a Poke at U.S. Peer Review Panels Senate Republicans have launched a new attack on peer review by proposing changes to how the U.S. government funds basic research. [ScienceInsider] Editorial Efforts to Save Leading Hungarian University Hit Hurdle The threatened Central European University in Budapest has been dealt a blow in its efforts to avert possible closure in Hungary. The country’s parliament voted to postpone, for a year, a decision that would allow the university to keep operating there. [Nature News] Editorial New Definitions of Scientific Units Are on the Horizon Revamped definitions of scientific units are on their way. In the biggest overhaul of the international system of units since its inception in 1960, a committee is set to redefine four basic units — the ampere, the kilogram, the kelvin and the mole — using relationships to fundamental constants, rather than abstract or arbitrary definitions. [Nature News] Editorial Top Chinese University to Consider Social-Media Posts in Researcher Evaluations One of China’s most prestigious universities plans to give some articles in newspapers and posts on major social-media outlets the same weight as peer-reviewed publications when it evaluates researchers. [Nature News] Editorial
| |
EVENTSNEW International Society for Stem Cell Research (ISSCR) 2018 Annual Meeting Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Assistant Member – Prostate Cancer (Fred Hutchinson Cancer Research Center) Postdoctoral Scientist – Prostate Oncobiology (CRUK Manchester Institute) Postdoctoral Position – Cancer Biology (The Henry Ford Health System) Research Fellow – Prostate Cancer (Norwegian University of Science and Technology) Doctoral Student – Prostate Cancer (Lund University) Director – Stanford Cancer Institute (Stanford University) Postdoctoral Position – Cancer Biology and Epigenetics (Duke University) Researcher – Cancer Biology (University of Cincinnati) Postdoctoral Position – Prostate Cancer (Baylor College of Medicine) Postdoctoral Position – Prostate Related Diseases (Baylor College of Medicine) Postdoctoral Fellow – Drug Discovery (Vancouver Prostate Centre) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|